Theranostic fluorescent probes

A Sharma, P Verwilst, M Li, D Ma, N Singh… - Chemical …, 2024‏ - ACS Publications
The ability to gain spatiotemporal information, and in some cases achieve spatiotemporal
control, in the context of drug delivery makes theranostic fluorescent probes an attractive …

Cancer stem cells: Advances in knowledge and implications for cancer therapy

X Chu, W Tian, J Ning, G **ao, Y Zhou… - … and Targeted Therapy, 2024‏ - nature.com
Cancer stem cells (CSCs), a small subset of cells in tumors that are characterized by self-
renewal and continuous proliferation, lead to tumorigenesis, metastasis, and maintain tumor …

A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia

AGX Zeng, S Bansal, L **, A Mitchell, WC Chen… - Nature medicine, 2022‏ - nature.com
The treatment landscape of acute myeloid leukemia (AML) is evolving, with promising
therapies entering clinical translation, yet patient responses remain heterogeneous, and …

Tumor microenvironment enriches the stemness features: the architectural event of therapy resistance and metastasis

P Nallasamy, RK Nimmakayala, S Parte, AC Are… - Molecular cancer, 2022‏ - Springer
Cancer divergence has many facets other than being considered a genetic term. It is a
tremendous challenge to understand the metastasis and therapy response in cancer …

Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer

Z Zeng, M Fu, Y Hu, Y Wei, X Wei, M Luo - Molecular Cancer, 2023‏ - Springer
Cancer stem cells (CSCs), initially identified in leukemia in 1994, constitute a distinct subset
of tumor cells characterized by surface markers such as CD133, CD44, and ALDH. Their …

NF‐κB signaling in inflammation and cancer

T Zhang, C Ma, Z Zhang, H Zhang, H Hu - MedComm, 2021‏ - Wiley Online Library
Since nuclear factor of κ‐light chain of enhancer‐activated B cells (NF‐κB) was discovered
in 1986, extraordinary efforts have been made to understand the function and regulating …

Leukemic stem cells and therapy resistance in acute myeloid leukemia

P Stelmach, A Trumpp - Haematologica, 2023‏ - pmc.ncbi.nlm.nih.gov
A major obstacle in the treatment of acute myeloid leukemia (AML) is refractory disease or
relapse after achieving remission. The latter arises from a few therapy-resistant cells within …

Hallmarks of cancer stemness

JJ Loh, S Ma - Cell Stem Cell, 2024‏ - cell.com
Cancer stemness is recognized as a key component of tumor development. Previously
coined" cancer stem cells"(CSCs) and believed to be a rare population with rigid …

Targeting metastatic cancer

K Ganesh, J Massagué - Nature medicine, 2021‏ - nature.com
Despite recent therapeutic advances in cancer treatment, metastasis remains the principal
cause of cancer death. Recent work has uncovered the unique biology of metastasis …

Cancer stem cells—origins and biomarkers: perspectives for targeted personalized therapies

L Walcher, AK Kistenmacher, H Suo, R Kitte… - Frontiers in …, 2020‏ - frontiersin.org
The use of biomarkers in diagnosis, therapy and prognosis has gained increasing interest
over the last decades. In particular, the analysis of biomarkers in cancer patients within the …